Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH)
NCT04216693 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · PHASE2 · withdrawn · last registry update 2023-02-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Administrative decision to terminate.” | – | Registry record, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ATP1A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-07-17Results posted on the registry: Boehringer Ingelheim, BI 730357 + CRESTOR® (NCT04590937)
- 2023-05-24Results posted on the registry: Windtree Therapeutics, Placebo + Istaroxime (NCT02617446)
- 2023-05-01Results posted on the registry: CMP Development, LLC, Digoxin 250 MCG Oral Tablet + Spironolactone 25 mg/ 5 mL S/F Suspension (NCT03909529)
- 2022-12-01Also stopped (withdrawn): Scripps Health, Placebo + Metolazone (NCT05633758)
- 2022-09-14Phase 3 first posted: University of Monastir, Digoxin 0.25 mg + Bisoprolol (NCT05540600)
- 2022-05-23Results posted on the registry: ViiV Healthcare, GSK3640254 200 mg + Caffeine 200 mg (NCT04425902)
- 2022-03-18Phase 3 first posted: Sunnybrook Health Sciences Centre, Magnesium sulfate and then Digoxin + Amiodarone (NCT05287191)
- 2022-03-04Results posted on the registry: GlaxoSmithKline, Gepotidacin + Cimetidine (NCT04493931)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision